Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants within vitroresistance to SR-BI-targeting agents-Reference-Cited by-同舟云学术

Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants within vitroresistance to SR-BI-targeting agents

Published:2014-07-30 Issue:5 Volume:60 Page:1508-1518
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Vercauteren Koen¹,Van Den Eede Naomi¹,Mesalam Ahmed Atef¹,Belouzard Sandrine²,Catanese Maria Teresa³⁴,Bankwitz Dorothea⁵,Wong-Staal Flossie⁶,Cortese Riccardo⁷,Dubuisson Jean²,Rice Charles M.³,Pietschmann Thomas⁵,Leroux-Roels Geert¹,Nicosia Alfredo⁷⁸,Meuleman Philip¹

Affiliation:

1. Department of Clinical Chemistry, Microbiology and Immunology; CEVAC; Gent Belgium

2. Institut Pasteur de Lille, Center for Infection & Immunity of Lille; Université Lille Nord de France; Inserm U1019 CNRS UMR8204, Université Lille Nord de France

3. Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease; Rockefeller University; New York NY USA

4. Department of Infectious Diseases; King's College London School of Medicine; Guy's Hospital London UK

5. Institute of Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research; a joint venture between the Medical School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI); Hannover Germany

6. iTherX Pharma Inc.; San Diego CA USA

7. CEINGE; Naples Italy

8. Department of Molecular Medicine and Medical Biotechnology; University of Naples Frederico II; Naples Italy

Funder

National Institutes of Health

Fonds Wetenschappelijk Onderzoek

Federaal Wetenschapsbeleid

European Commission

Helmholtz Association

Deutsche Forschungsgemeinschaft

Ghent University

The Greenberg Medical Research Institute